InvestSMART

Kazia Therapeutics Limited (ASX: KZA) - Announcements

DELISTED - Current share price for KZA : $0.080

ASX company news and announcements for Kazia Therapeutics Limited (KZA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Kazia Therapeutics Limited (KZA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Kazia Therapeutics Limited (KZA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Kazia Therapeutics Limited (KZA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Notice of General Meeting/Proxy Form 13 Oct 2021 8:27AM $1.440 $0.080 fallen by 94.44%
- Kazia AGM date 20 Sep 2021 10:07AM $1.420 $0.080 fallen by 94.37%
- Notification of cessation of securities - KZA 10 Sep 2021 4:21PM $1.450 $0.080 fallen by 94.48%
- Notification regarding unquoted securities - KZA 9 Sep 2021 11:32AM $1.400 $0.080 fallen by 94.29%
- Kazia's EVT801 phase I trial receives regulatory approval 2 Sep 2021 8:43AM $1.430 $0.080 fallen by 94.41%
- Shareholder information - amendment 2 Sep 2021 8:30AM $1.430 $0.080 fallen by 94.41%
- Change in Directors interests 30 Aug 2021 10:14AM $1.415 $0.080 fallen by 94.35%
- Kazia Annual Report to shareholders 26 Aug 2021 8:25AM $1.245 $0.080 fallen by 93.57%
- Kazia Corporate Governance Statement 26 Aug 2021 8:20AM $1.245 $0.080 fallen by 93.57%
- Kazia Appendix 4G 26 Aug 2021 8:20AM $1.245 $0.080 fallen by 93.57%
- Kazia Appendix 4E 26 Aug 2021 8:20AM $1.245 $0.080 fallen by 93.57%
- Kazia corporate presentation 16 Aug 2021 9:49AM $1.240 $0.080 fallen by 93.55%
- Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2021 8:57AM $1.250 $0.080 fallen by 93.60%
- Kazia update 30 Jun 2021 9:50AM $1.280 $0.080 fallen by 93.75%
- Manufacturing patents granted for paxalisib 24 Jun 2021 9:27AM $1.300 $0.080 fallen by 93.85%
- Ceasing to be a substantial holder 21 Jun 2021 2:45PM $1.325 $0.080 fallen by 93.96%
- Kazia launches new paxalisib phase II clinical trial 15 Jun 2021 9:08AM $1.400 $0.080 fallen by 94.29%
- Kazia paxilisib in Dana Farber study enrols first patient 7 Jun 2021 9:40AM $1.270 $0.080 fallen by 93.70%
- Appendix 3Y for 3 directors 2 Jun 2021 2:59PM $1.210 $0.080 fallen by 93.39%
- Change in substantial holding 27 May 2021 8:25AM $1.145 $0.080 fallen by 93.01%
- Appendix 2A 21 May 2021 5:33PM $1.240 $0.080 fallen by 93.55%
- Change in substantial holding 10 May 2021 8:17AM $1.360 $0.080 fallen by 94.12%
- Change of directors interests * 3 4 May 2021 9:36AM $1.395 $0.080 fallen by 94.27%
- Cleansing notice 30 Apr 2021 12:24PM $1.380 $0.080 fallen by 94.20%
- Appendix 4C - quarterly 30 Apr 2021 12:22PM $1.380 $0.080 fallen by 94.20%

201 - 225 of 476 results

Page 9 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.